ArticleNature communications2022
A genetic toolkit and gene switches to limit Mycoplasma growth for biosafety applications.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- A genetic manipulation tool based on the GP35 recombinase for targeted gene editing in mycoplasmas of ruminants.The Journal of biological chemistry · 2026Article
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases.Advanced drug delivery reviews · 2025Review
- A versatile plug and play bacterial chassis based on a fast-growing Mycoplasma species.Nucleic acids research · 2025Article
- A genetic safeguard for eliminating target genes in synthetic probiotics in a gut environment.iScience · 2025Article
- Robust and highly efficient transformation method for a minimal mycoplasma cell.Journal of bacteriology · 2025Article
- Bacterial live therapeutics for human diseases.Molecular systems biology · 2024Review
- Engineering stringent genetic biocontainment of yeast with a protein stability switch.Nature communications · 2024Article
- Mammalian cell growth characterisation by a non-invasive plate reader assay.Nature communications · 2024Article
- Engineering bacterial theranostics: from logic gates toFrontiers in bioengineering and biotechnology · 2024Review
- Review
- Gene editing tools for mycoplasmas: references and future directions for efficient genome manipulation.Frontiers in microbiology · 2023Review
- Bacterial expression of a designed single-chain IL-10 prevents severe lung inflammation.Molecular systems biology · 2023Article
- A genetic toolkit and gene switches to limit Mycoplasma growth for biosafety applications.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasmas have exceptionally streamlined genomes and are strongly adapted to their many hosts, which provide them with essential nutrients. Owing to their relative genomic simplicity, Mycoplasmas have been used to develop chassis for biotechnological applications. However, the dearth of robust and precise toolkits for genomic manipulation and tight regulation has hindered any substantial advance. Herein we describe the construction of a robust genetic toolkit for M. pneumoniae, and its successful deployment to engineer synthetic gene switches that control and limit Mycoplasma growth, for biosafety containment applications. We found these synthetic gene circuits to be stable and robust in the long-term, in the context of a minimal cell. With this work, we lay a foundation to develop viable and robust biosafety systems to exploit a synthetic Mycoplasma chassis for live attenuated vectors for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.